A note on ivermectin:

This page contains the medical evidence in support of the individual medical therapies that make up our MATH+ Hospital Treatment Protocol for COVID-19 as well as I-PREVENT, I-CARE and I-RECOVER. In October 2020, we added ivermectin to our COVID-19 protocols, which we regard as a core medication in the prevention and treatment of COVID-19. That evidence has its own section: Ivermectin in COVID-19.

The work of the FLCCC is based on a substantial body of evidence that supports our recommendations. The doctors of the FLCCC have themselves conducted and published peer-reviewed studies, as well as systematic reviews and meta-analyses. They have also reviewed and referenced tens of thousands of other studies in support of these positions. Most of these materials are readily available online.

We are currently working on building out a detailed reference library to help users easily navigate the research cited in our protocols. In the meantime, you can download the list of over 800 studies on which our protocols are based.

Download Studies Referenced in FLCCC Protocols

This page contains the medical evidence in support of the individual medical therapies that make up our MATH+ Hospital Treatment Protocol for COVID-19 as well as I-PREVENT, I-CARE and I-RECOVER.  In October 2020, we added ivermectin to our COVID-19 protocols, which we regard as a core medication in the prevention and treatment of COVID-19.  That evidence has its own section: Ivermectin in COVID-19.

Corticosteroid therapy is one of the most effective interventions in COVID-19 and MATH+. From early March 2020, when the FLCCC team of physicians first came together to study and create treatment protocols for fighting the novel disease, the team, guided by Dr. G. Umberto Meduri’s expertise in corticosteroid use, placed methylprednisolone at the head — as the “M” — in its MATH+ hospital treatment formula. As a result, the two hospitals using the MATH+ formula had mortality rates of no higher than 6%, when most hospitals lost as many as 80% of their seriously ill COVID patients. This was months before the landmark RECOVERY trial convinced world authorities to allow and advocate for the use of steroids in treating the inflammatory stage of the disease. Publications listed below range from large scale observational studies demonstrating large impacts on mortality in the prior pandemics of SARS and H1N1, through the landmark RECOVERY trial done in the United Kingdom against COVID-19, to numerous and increasing COVID-19 retrospective cohort studies published from Italy, China, Spain, and the United States. In addition, a scientific review of the evidence supporting methylprednisolone in COVID-19 authored by FLCCC Alliance member Dr. G. Umberto Meduri can be found here.


Jun 1, 2021
Is Methylprednisolone Better than Dexamethasone for Severe COVID-19?
Daniel D. Dressler, MD, MSc, MHM, FACP


Oct 7, 2020
The ten reasons why corticosteroid therapy reduces mortality in severe COVID-19
Yaseen M. Arabi, George P. Chrousos & G. Umberto Meduri


Sep 22, 2020
SARS-CoV-2 organising pneumonia: ‘Has there been a widespread failure to identify and treat this prevalent condition in COVID-19?’
Pierre Kory (FLCCC Alliance) and Jeffrey P. Kanne


Sep 12, 2020
Prolonged Low-Dose Methylprednisolone in Patients With Severe COVID-19 Pneumonia
Francesco Salton, Paola Confalonieri, G. Umberto Meduri et al.


Sep 2, 2020
Timing is crucial and hydrocortisone should be started within the first 12 hours after shock onset
Cohort study: “Evaluation of the Initiation Timing of Hydrocortisone in Adult Patients With Septic Shock”


Sep 2, 2020
Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19
The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial


Sep 2, 2020
Effect of hydrocortisone on 21-day mortality or respiratory support among critically ill patients with COVID-19
A Randomized Clinical Trial


Sep 2, 2020
Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19
The CoDEX Randomized Clinical Trial


Jun 25, 2020